Kinex appoints Dr David Hangauer CSO
This article was originally published in Scrip
Kinex's board of directors has appointed Dr David Hangauer chief scientific officer. Dr Hangauer previously served as founding senior vice-president of research for Kinex, and discovered and designed both of the company's lead products, Mimetica and Opal.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.